Precision Medicine in Lung Cancer Screening: A Paradigm Shift in Early Detection

Strategic Insights -

A new study from Kaohsiung Veterans General Hospital has highlighted the limitations of traditional lung cancer screening strategies, which often rely on age and smoking history. The research emphasizes the need for precision medicine, which tailors screening protocols to individual risk profiles using clinical, genetic, environmental, and radiological data. This approach has the potential to optimize early detection, minimize harm, and extend the benefits of lung cancer screening to broader and more diverse populations.

Key Takeaways:

  • Lung cancer remains the leading cause of cancer-related mortality globally, largely due to late-stage diagnoses, with low-dose computed tomography (LDCT) improving early detection and reducing mortality in high-risk populations.
  • Traditional screening strategies often adopt a one-size-fits-all approach, leading to limitations such as overdiagnosis, false positives, and the underrepresentation of non-smokers, particularly prevalent in Asian populations.
  • Precision medicine offers a transformative solution by integrating clinical, genetic, environmental, and radiological data to tailor screening protocols to individual risk profiles, leveraging emerging tools like risk prediction models, radiomics, artificial intelligence (AI), liquid biopsies, polygenic risk scores (PRSs), and molecular biomarkers.
  • Incorporation of these innovations into clinical workflows, alongside shared decision-making (SDM) and robust data infrastructure, represents a paradigm shift in lung cancer prevention.
  • Challenges related to health equity, algorithmic bias, and system integration must be addressed to ensure the successful implementation of precision medicine in lung cancer screening.
  • This review emphasizes the need for interdisciplinary collaboration and population-specific strategies to realize the full potential of precision medicine in reducing the global burden of lung cancer.

Statistics:

  • Lung cancer is the leading cause of cancer-related mortality globally.
  • Low-dose computed tomography (LDCT) has improved early detection and reduced mortality in high-risk populations.
  • Precision medicine has the potential to optimize early detection, minimize harm, and extend the benefits of lung cancer screening to broader and more diverse populations.
  • 15% of lung cancer cases are diagnosed at an early stage, leading to a 5-year survival rate of 56%.
  • 50% of lung cancer cases are diagnosed in non-smokers, particularly prevalent in Asian populations.

Sources:

  • Precision Medicine in Lung Cancer Screening: A Paradigm Shift in Early Detection-Precision Screening for Lung Cancer. Diagnostics, 2025,15(12):1562. (Diagnostics - http://www.mdpi.com/journal/diagnostics)
  • NewsRx. Studies from Kaohsiung Veterans General Hospital Have Provided New Data on Personalized Medicine (Precision Medicine in Lung Cancer Screening: A Paradigm Shift in Early Detection-Precision Screening for Lung Cancer). Health & Medicine Week. July 11, 2025; p 6837.